Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (521-530 of 744) with videos related to

Pageof 75
Sort By:
Cancers|May 28, 2022
Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during LockdownLisa Kostner, Sara Elisa Cerminara, Gustavo Santo Pedro Pamplona, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
Cancer Cell|March 16, 2016
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma TherapyMichael P Smith, Holly Brunton, Emily J Rowling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS TrialPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2018
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitorsAlvaro Moreira, Carmen Loquai, Claudia Pföhler, et al.
Leukemia & Lymphoma|January 14, 2012
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibitionReinhard Dummer, Marc Beyer, Kenneth Hymes, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete responseFlorentia Dimitriou, Anne Zaremba, Clara Allayous, et al.
Cancer Research|October 14, 2021
Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma ProgressionAnnalisa Saltari, Andreas Dzung, Marika Quadri, et al.
Oncoimmunology|January 27, 2017
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanomaMarcel A Deken, Jules Gadiot, Ekaterina S Jordanova, et al.
Blood|June 2, 2007
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Elise Olsen, Eric Vonderheid, Nicola Pimpinelli, et al.
Pageof 75

Showing results (521-530 of 744) with videos related to

Sort By:
Pageof 75
Cancers|May 28, 2022
Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during LockdownLisa Kostner, Sara Elisa Cerminara, Gustavo Santo Pedro Pamplona, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
Cancer Cell|March 16, 2016
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma TherapyMichael P Smith, Holly Brunton, Emily J Rowling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS TrialPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2018
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitorsAlvaro Moreira, Carmen Loquai, Claudia Pföhler, et al.
Leukemia & Lymphoma|January 14, 2012
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibitionReinhard Dummer, Marc Beyer, Kenneth Hymes, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete responseFlorentia Dimitriou, Anne Zaremba, Clara Allayous, et al.
Cancer Research|October 14, 2021
Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma ProgressionAnnalisa Saltari, Andreas Dzung, Marika Quadri, et al.
Oncoimmunology|January 27, 2017
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanomaMarcel A Deken, Jules Gadiot, Ekaterina S Jordanova, et al.
Blood|June 2, 2007
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Elise Olsen, Eric Vonderheid, Nicola Pimpinelli, et al.
Pageof 75